Trials / Recruiting
RecruitingNCT05927428
Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis
An Open-Label, Multi-Center, Phase 2 Dose Ranging Study of BRM424 Ophthalmic Solution in Patients With Neurotrophic Keratitis (NK)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- BRIM Biotechnology Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to obtain initial efficacy of BRM424 in patients with Stage 2 and Stage 3 NK and evaluate safety and tolerability.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BRM424 Ophthalmic Solution - Dose1 | A topical drop of BRM424 ophthalmic solution. |
| DRUG | BRM424 Ophthalmic Solution - Dose2 | A topical drop of BRM424 ophthalmic solution. |
Timeline
- Start date
- 2024-07-31
- Primary completion
- 2025-08-30
- Completion
- 2025-11-30
- First posted
- 2023-07-03
- Last updated
- 2024-10-28
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05927428. Inclusion in this directory is not an endorsement.